• Title of article

    Biologically active oligodeoxyribonucleotides—IX.1 Synthesis and anti-HIV-1 activity of hexadeoxyribonucleotides, TGGGAG, bearing 3′- and 5′-end-modification Original Research Article

  • Author/Authors

    Makoto Koizumi، نويسنده , , Rika Koga، نويسنده , , Hitoshi Hotoda، نويسنده , , Kenji Momota، نويسنده , , Toshinori Ohmine، نويسنده , , Hidehiko Furukawa، نويسنده , , Toshinori Agatsuma، نويسنده , , Takashi Nishigaki، نويسنده , , Koji Abe، نويسنده , , Toshiyuki Kosaka، نويسنده , , Shinya Tsutsumi، نويسنده , , Junko Sone، نويسنده , , Masakatsu Kaneko، نويسنده , , Satoshi Kimura، نويسنده , , Kaoru Shimada، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 1997
  • Pages
    9
  • From page
    2235
  • To page
    2243
  • Abstract
    We have determined that hexadeoxyribonucleotides (5′TGGGAG3′), with modified aromatic groups such as a trityl group at the 5′-end, have anti-HIV-1 activity in vitro. The 6-mer bearing a 3,4-dibenzyloxybenzyl (3,4-DBB) group at the 5′-end had the most potent activity and the least cytotoxicity. When the 3′-end of the 5′-(3,4-DBB)-modified 6-mer was substituted with a 2-hydroxyethylphosphate, a 2-hydroxyethylthiophosphate, or a methylphosphate group at the 3′-end, anti-HIV-1 activity increased. Moreover, among various 3′- and 5′-end-modified 6-mers that were tested, the 6-mer (R-95288) bearing a 3,4-DBB group at the 5′-end and a 2-hydroxyethylphosphate group at the 3′-end was the most stable, when incubated with mouse, rat, or human plasma. Therefore, R-95288 was chosen as the best candidate for possible use in therapy on the basis of its anti-HIV-1 activity.
  • Keywords
    nuclease-resistance , Aptamer , 4-dibenzyloxybenzyl , 2-hydroxyethylphosphate , Quadruplex , 3
  • Journal title
    Bioorganic and Medicinal Chemistry
  • Serial Year
    1997
  • Journal title
    Bioorganic and Medicinal Chemistry
  • Record number

    1301422